Investigating Tralokinumab-Related Adverse Events in Treating Atopic Dermatitis: Insights from the FAERS Database
February 2026
in “
Frontiers in Immunology
”
Studysummary In this study analyzing FDA data, researchers found that tralokinumab was associated with higher reports of conjunctivitis and keratitis compared to dupilumab, while dupilumab had more frequent injection site reactions, highlighting potential risks for clinical monitoring in atopic dermatitis treatments.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
This study analyzed 1,770 adverse event (AE) reports related to tralokinumab, a treatment for atopic dermatitis, from the FAERS database. Notable AEs included eczema herpeticum, generalized exfoliative dermatitis, alopecia, skin exfoliation, and blepharitis, with most occurring within the first month of treatment. Compared to dupilumab, tralokinumab had a higher incidence of conjunctivitis and keratitis but fewer injection site reactions. The study highlights the need for clinical monitoring and further research to understand these AEs and improve patient safety.
